Greg Hughes

Greg Hughes is a Senior Principal Scientist at Merck, based in Scotch Plains, New Jersey.1 He has extensive experience in process chemistry, focusing on developing cost-effective and environmentally sustainable manufacturing processes for the pharmaceutical industry.

Career Progression

Greg Hughes has had a long and distinguished career at Merck:

• He currently holds the position of Senior Principal Scientist, which he has occupied since October 2020.1
• Prior to this, he served as a Principal Scientist at Merck from May 2016 to October 2020.1
• Earlier in his career, he held the role of Executive Director of Enabling Technologies in Process Chemistry at Merck from 2002 to October 2013, where he managed groups in Biocatalysis, Catalysis, Automation, and Flow Chemistry.1

Education and Early Career

Hughes has a strong academic background:

• He earned his Bachelor of Science in Chemistry from the University of New Brunswick (1990-1994).1
• He then completed his Ph.D. in Organic Chemistry at the University of Toronto (1996-2000).1
• Following his doctoral studies, he pursued postdoctoral research in Asymmetric Catalysis at M.I.T. from 2000 to 2002.1

Research and Expertise

Greg Hughes is highly cited in his field, with 4937 citations to his name, indicating significant contributions to pharmaceutical research and process chemistry.3 His work focuses on:

• Developing beautiful, cost-effective, and environmentally sustainable manufacturing processes.1
• Expertise in areas such as biocatalysis, catalysis, automation, and flow chemistry.1

Other Professional Experience

Outside of his primary role at Merck, Hughes has also:

• Served as Vice President of Business Development at Codexis, Inc. from October 2013 to October 2015.1
• Contributed to diversity initiatives in chemistry, being featured on the DiversifyChem website, which aims to bring visibility to underrepresented groups in the chemistry community.2

Greg Hughes' extensive experience and contributions to process chemistry make him a respected figure in the pharmaceutical industry and academic circles.